• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

肝门部胆管癌化疗疗效相关胆汁微小RNA的筛选及分子机制研究

Screening and molecular mechanism research on bile microRNAs associated with chemotherapy efficacy in perihilar cholangiocarcinoma.

作者信息

Fu Shijie, Du Haizhen, Dai Yuyang, Zheng Kanglian, Cao Guang, Xu Liang, Zhong Yujie, Niu Chuanxin, Kong Yan, Wang Xiaodong

机构信息

Department of Interventional Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing 100000, China.

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing 100142, China.

出版信息

iScience. 2024 Dec 4;27(12):111437. doi: 10.1016/j.isci.2024.111437. eCollection 2024 Dec 20.

DOI:10.1016/j.isci.2024.111437
PMID:39717085
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11664176/
Abstract

The efficacy of hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin (OXA) and 5-fluorouracil (5-Fu) for treating advanced perihilar cholangiocarcinoma (pCCA) has been demonstrated, yet the survival benefits of HAIC for pCCA patients vary. Here, we aimed to screen out HAIC resistance-related bile microRNAs (miRNAs) and explore the functions of specific bile miRNAs in pCCA based on high-throughput sequencing. Levels of bile miR-532-3p, miR-1250-5p, and miR-4772-5p were related to the survival of advanced pCCA patients after HAIC. However, only overexpression of miR-532-3p promoted OXA/5-Fu resistance, and downregulation of its expression improved sensitivity to OXA/5-Fu. Mechanistic investigations revealed secreted protein acidic and rich in cysteine (SPARC) as the direct target of miR-532-3p. Our study reveals that bile miR-532-3p, miR-1250-5p, and miR-4772-5p may serve as survival biomarkers in advanced pCCA patients after HAIC and that bile miR-532-3p promotes resistance to HAIC with OXA and 5-Fu via negatively regulating SPARC expression.

摘要

肝动脉灌注化疗（HAIC）联合奥沙利铂（OXA）和5-氟尿嘧啶（5-Fu）治疗晚期肝门部胆管癌（pCCA）的疗效已得到证实，但HAIC对pCCA患者的生存获益存在差异。在此，我们旨在基于高通量测序筛选出与HAIC耐药相关的胆汁微小RNA（miRNA），并探索特定胆汁miRNA在pCCA中的功能。胆汁miR-532-3p、miR-1250-5p和miR-4772-5p的水平与晚期pCCA患者接受HAIC后的生存相关。然而，只有miR-532-3p的过表达促进了OXA/5-Fu耐药，而其表达下调则提高了对OXA/5-Fu的敏感性。机制研究表明，富含半胱氨酸的酸性分泌蛋白（SPARC）是miR-532-3p的直接靶点。我们的研究表明，胆汁miR-532-3p、miR-1250-5p和miR-4772-5p可能作为晚期pCCA患者接受HAIC后的生存生物标志物，并且胆汁miR-532-3p通过负向调节SPARC表达促进对OXA和5-Fu的HAIC耐药。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f889/11664176/afed26db2909/gr10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f889/11664176/66d3c96d8328/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f889/11664176/9e27d1dee626/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f889/11664176/59646075a75b/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f889/11664176/6721da9a5ffc/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f889/11664176/936e7873f0bb/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f889/11664176/8da377960b66/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f889/11664176/b439c2f21ae6/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f889/11664176/c67cd55766cf/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f889/11664176/c63aed44b052/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f889/11664176/5d3d9e6188a8/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f889/11664176/afed26db2909/gr10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f889/11664176/66d3c96d8328/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f889/11664176/9e27d1dee626/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f889/11664176/59646075a75b/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f889/11664176/6721da9a5ffc/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f889/11664176/936e7873f0bb/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f889/11664176/8da377960b66/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f889/11664176/b439c2f21ae6/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f889/11664176/c67cd55766cf/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f889/11664176/c63aed44b052/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f889/11664176/5d3d9e6188a8/gr9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f889/11664176/afed26db2909/gr10.jpg

相似文献

1
Screening and molecular mechanism research on bile microRNAs associated with chemotherapy efficacy in perihilar cholangiocarcinoma.肝门部胆管癌化疗疗效相关胆汁微小RNA的筛选及分子机制研究
iScience. 2024 Dec 4;27(12):111437. doi: 10.1016/j.isci.2024.111437. eCollection 2024 Dec 20.
2
Bile-derived circulating extracellular miR-30d-5p and miR-92a-3p as potential biomarkers for cholangiocarcinoma.胆汁来源的循环细胞外 miR-30d-5p 和 miR-92a-3p 作为胆管癌的潜在生物标志物。
Hepatobiliary Pancreat Dis Int. 2020 Feb;19(1):41-50. doi: 10.1016/j.hbpd.2019.10.009. Epub 2019 Nov 8.
3
MiR-22-3p Inhibits 5-Fluorouracil Resistance in Cholangiocarcinoma Cells Through PTEN/PI3K/AKT Axis.微小RNA-22-3p通过PTEN/PI3K/AKT轴抑制胆管癌细胞对5-氟尿嘧啶的耐药性
Assay Drug Dev Technol. 2024 Jul;22(5):217-228. doi: 10.1089/adt.2024.007. Epub 2024 Jul 5.
4
NLCECA score: a serum inflammatory-tumor biomarker score to predict survival of advanced perihilar cholangiocarcinoma after hepatic arterial infusion chemotherapy.NLCECA 评分：一种血清炎症-肿瘤生物标志物评分，可预测肝动脉灌注化疗后晚期肝门部胆管癌的生存情况。
Sci Rep. 2024 Feb 23;14(1):4466. doi: 10.1038/s41598-024-53883-7.
5
CG200745, an HDAC inhibitor, induces anti-tumour effects in cholangiocarcinoma cell lines via miRNAs targeting the Hippo pathway.CG200745，一种组蛋白去乙酰化酶抑制剂，通过靶向 Hippo 通路的 miRNAs 诱导胆管癌细胞系产生抗肿瘤作用。
Sci Rep. 2017 Sep 7;7(1):10921. doi: 10.1038/s41598-017-11094-3.
6
The expression of exosomal and cellular miRNAs in predicting oxaliplatin resistance in colorectal cancer cells: an in silico and in vitro study.外泌体和细胞微小RNA在预测大肠癌细胞对奥沙利铂耐药性中的表达：一项计算机模拟和体外研究
BMC Cancer. 2025 Jan 9;25(1):46. doi: 10.1186/s12885-024-13392-2.
7
The ATO/miRNA-885-5p/MTPN axis induces reversal of drug-resistance in cholangiocarcinoma.ATO/miRNA-885-5p/MTPN 轴诱导胆管癌耐药逆转。
Cell Oncol (Dordr). 2021 Aug;44(4):907-916. doi: 10.1007/s13402-021-00610-3. Epub 2021 Jun 25.
8
LncRNA FALEC increases the proliferation, migration and drug resistance of cholangiocarcinoma through competitive regulation of miR-20a-5p/SHOC2 axis.长链非编码 RNA FALEC 通过竞争性调节 miR-20a-5p/SHOC2 轴增加胆管癌的增殖、迁移和耐药性。
Aging (Albany NY). 2023 May 9;15(9):3759-3770. doi: 10.18632/aging.204709.
9
Analysis of MicroRNA in Bile Cytologic Samples Is Useful for Detection and Diagnosis of Extrahepatic Cholangiocarcinoma.胆汁细胞学样本中 microRNA 的分析有助于肝外胆管癌的检测和诊断。
Am J Clin Pathol. 2022 Jul 1;158(1):122-131. doi: 10.1093/ajcp/aqac015.
10
Low miR-224-5p in exosomes confers colorectal cancer 5-FU resistance by upregulating S100A4.外泌体中低水平的miR-224-5p通过上调S100A4赋予结直肠癌5-氟尿嘧啶耐药性。
Drug Resist Updat. 2025 Mar;79:101211. doi: 10.1016/j.drup.2025.101211. Epub 2025 Feb 6.

本文引用的文献

1
Circulating miRNAs modulating systemic low-grade inflammation and affecting neurodegeneration.循环 miRNA 调节全身低度炎症并影响神经退行性变。
Prog Neuropsychopharmacol Biol Psychiatry. 2024 Dec 20;135:111130. doi: 10.1016/j.pnpbp.2024.111130. Epub 2024 Aug 28.
2
A comprehensive overview of liquid biopsy applications in pediatric solid tumors.液体活检在儿科实体瘤中的应用综述
NPJ Precis Oncol. 2024 Aug 3;8(1):172. doi: 10.1038/s41698-024-00657-z.
3
Identification and Characterization of Chemotherapy-Resistant High-Risk Neuroblastoma Persister Cells.
化疗耐药高危神经母细胞瘤持久性细胞的鉴定与特征分析
Cancer Discov. 2024 Dec 2;14(12):2387-2406. doi: 10.1158/2159-8290.CD-24-0046.
4
Molecular mechanism of MLCK1 inducing 5-Fu resistance in colorectal cancer cells through activation of TNFR2/NF-κB pathway.肌球蛋白轻链激酶1（MLCK1）通过激活肿瘤坏死因子受体2（TNFR2）/核因子κB（NF-κB）途径诱导大肠癌细胞对5-氟尿嘧啶耐药的分子机制
Discov Oncol. 2024 May 12;15(1):159. doi: 10.1007/s12672-024-01019-8.
5
SPARC: a potential target for functional nanomaterials and drugs.SPARC：功能性纳米材料和药物的潜在靶点。
Front Mol Biosci. 2023 Jul 28;10:1235428. doi: 10.3389/fmolb.2023.1235428. eCollection 2023.
6
Bile exosomal miR-182/183-5p increases cholangiocarcinoma stemness and progression by targeting HPGD and increasing PGE2 generation.胆汁外泌体 miR-182/183-5p 通过靶向 HPGD 增加 PGE2 的生成，从而增加胆管癌细胞干性和进展。
Hepatology. 2024 Feb 1;79(2):307-322. doi: 10.1097/HEP.0000000000000437. Epub 2023 May 5.
7
inhibited the methylation of to suppress the progression of PC by targeting .抑制 的甲基化来抑制 PC 的进展，靶向 。
Life Sci Alliance. 2023 Apr 21;6(5). doi: 10.26508/lsa.202201703. Print 2023 Apr.
8
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.帕博利珠单抗联合吉西他滨和顺铂与单纯吉西他滨和顺铂治疗晚期胆道癌患者的比较（KEYNOTE-966）：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16.
9
New Challenges in the Management of Cholangiocarcinoma: The Role of Liver Transplantation, Locoregional Therapies, and Systemic Therapy.胆管癌管理中的新挑战：肝移植、局部区域治疗及全身治疗的作用
Cancers (Basel). 2023 Feb 15;15(4):1244. doi: 10.3390/cancers15041244.
10
Immunology and immunotherapy of cholangiocarcinoma.胆管癌的免疫学和免疫疗法。
Nat Rev Gastroenterol Hepatol. 2023 Jun;20(6):349-365. doi: 10.1038/s41575-022-00741-4. Epub 2023 Jan 25.